Funded by the National Institute on Aging (NIA), and sponsored by Vivoryon Therapeutics, the VIVA-MIND clinical trial is evaluating whether the investigational oral drug varoglutamstat is safe and can slow down or halt the progression of Alzheimer’s disease (AD). Varoglutamstat aims to reduce N3pE, a specific and toxic form of the amyloid protein, which accumulates in the brains of people with AD.
About Mild Cognitive Impairment and Mild Alzheimer’s Disease
The VIVA-MIND clinical research trial is designed for people who are age 50-89, and experiencing significant memory concerns, or who have already been diagnosed with Mild Cognitive Impairment (MCI) or mild Alzheimer’s disease (AD). This stage of the disease, MCI through mild AD, is also known as “early AD”.